PURPOSE:Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylactic budesonide (Entocort EC), a nonabsorbed oral steroid, reduced the rate of grade >or=2 diarrhea in ipilimumab-treated patients with advanced melanoma. EXPERIMENTAL DESIGN:Previously treated and treatment-naïve patients (N = 115) with unresectable stage III or IV melanoma receivedopen-label ipilimumab (10 mg/kg every 3 weeks for four doses) with daily blinded budesonide (group A) or placebo (group B) through week 16. The first scheduled tumor evaluation was at week 12; eligible patients received maintenance treatment starting at week 24. Diarrhea was assessed using Common Terminology Criteria for Adverse Events (CTCAE) 3.0. Patients kept a diary describing their bowel habits. RESULTS:Budesonide did not affect the rate of grade >or=2 diarrhea, which occurred in 32.7% and 35.0% of patients in groups A and B, respectively. There were no bowel perforations or treatment-related deaths. Best overall response rates were 12.1% in group A and 15.8% in group B, with a median overall survival of 17.7 and 19.3 months, respectively. Within each group, the disease control rate was higher in patients with grade 3 to 4 irAEs than in patients with grade 0 to 2 irAEs, although many patients with grade 1 to 2 irAEs experienced clinical benefit. Novel patterns of response to ipilimumab were observed. CONCLUSIONS:Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events. Budesonide should not be used prophylactically for grade >or=2 diarrhea associated with ipilimumab therapy.
RCT Entities:
PURPOSE:Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylactic budesonide (Entocort EC), a nonabsorbed oral steroid, reduced the rate of grade >or=2 diarrhea in ipilimumab-treated patients with advanced melanoma. EXPERIMENTAL DESIGN: Previously treated and treatment-naïve patients (N = 115) with unresectable stage III or IV melanoma received open-label ipilimumab (10 mg/kg every 3 weeks for four doses) with daily blinded budesonide (group A) or placebo (group B) through week 16. The first scheduled tumor evaluation was at week 12; eligible patients received maintenance treatment starting at week 24. Diarrhea was assessed using Common Terminology Criteria for Adverse Events (CTCAE) 3.0. Patients kept a diary describing their bowel habits. RESULTS:Budesonide did not affect the rate of grade >or=2 diarrhea, which occurred in 32.7% and 35.0% of patients in groups A and B, respectively. There were no bowel perforations or treatment-related deaths. Best overall response rates were 12.1% in group A and 15.8% in group B, with a median overall survival of 17.7 and 19.3 months, respectively. Within each group, the disease control rate was higher in patients with grade 3 to 4 irAEs than in patients with grade 0 to 2 irAEs, although many patients with grade 1 to 2 irAEs experienced clinical benefit. Novel patterns of response to ipilimumab were observed. CONCLUSIONS:Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events. Budesonide should not be used prophylactically for grade >or=2 diarrhea associated with ipilimumab therapy.
Authors: Jianda Yuan; Matthew Adamow; Brian A Ginsberg; Teresa S Rasalan; Erika Ritter; Humilidad F Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L Terzulli; Deborah Kuk; Katherine S Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A Jungbluth; James P Allison; Lloyd J Old; Jedd D Wolchok; Sacha Gnjatic Journal: Proc Natl Acad Sci U S A Date: 2011-09-20 Impact factor: 11.205
Authors: Brian A Ginsberg; Humilidad F Gallardo; Teresa S Rasalan; Matthew Adamow; Zhenyu Mu; Sapna Tandon; Barrett B Bewkes; Ruth-Ann Roman; Paul B Chapman; Gary K Schwartz; Richard D Carvajal; Katherine S Panageas; Stephanie L Terzulli; Alan N Houghton; Jianda D Yuan; Jedd D Wolchok Journal: Clin Cancer Res Date: 2010-07-20 Impact factor: 12.531
Authors: Peter A Prieto; James C Yang; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Donald E White; Catherine L Levy; Steven A Rosenberg; Giao Q Phan Journal: Clin Cancer Res Date: 2012-01-23 Impact factor: 12.531
Authors: Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Christopher A Barker; Michael A Postow; Shaheer A Khan; Kathryn Beal; Preeti K Parhar; Yoshiya Yamada; Nancy Y Lee; Jedd D Wolchok Journal: Cancer Immunol Res Date: 2013-07-25 Impact factor: 11.151